search
Back to results

Immunological and Clinical Responses to Zinc in Children With Diarrhoea

Primary Purpose

Diarrhoea

Status
Completed
Phase
Phase 3
Locations
Bangladesh
Study Type
Interventional
Intervention
Zinc
Sponsored by
International Centre for Diarrhoeal Disease Research, Bangladesh
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diarrhoea focused on measuring Zinc treatment, supplementation, Enterotoxigenic E. coli, diarrhoea

Eligibility Criteria

6 Months - 24 Months (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children 6-24 months of age with acute childhood diarrheal illness.

Exclusion Criteria:

  • Severe dehydration, suspected cholera or pneumonia, chronic illness, bipedal edema (seriously ill children will be referred to ICDDR,B/Shishu Hospital).
  • The child is currently receiving zinc (as a treatment or supplement)
  • Wt/length, z-score below -3 (these children will be referred to ICDDR,B/ Shishu Hospital)
  • Already participating in another study involving nutritional or therapeutic interventions

Sites / Locations

  • ICDDR,B. Mirpur Field Site

Outcomes

Primary Outcome Measures

To evaluate innate and adaptive immune response.
Future occurrence of acute diarrhoea, ARI and impetigo.

Secondary Outcome Measures

Full Information

First Posted
December 5, 2006
Last Updated
February 19, 2009
Sponsor
International Centre for Diarrhoeal Disease Research, Bangladesh
Collaborators
Bill and Melinda Gates Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT00408356
Brief Title
Immunological and Clinical Responses to Zinc in Children With Diarrhoea
Official Title
Immunological and Clinical Responses to Zinc: A Randomized, Double-Blind Trial of Zinc Treatment vs. Zinc Treatment Plus Daily Supplementation for 3 Months Among Children Under 2 Years of Age With an Acute Diarrheal Illness.
Study Type
Interventional

2. Study Status

Record Verification Date
February 2009
Overall Recruitment Status
Completed
Study Start Date
November 2004 (undefined)
Primary Completion Date
August 2006 (Actual)
Study Completion Date
November 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
International Centre for Diarrhoeal Disease Research, Bangladesh
Collaborators
Bill and Melinda Gates Foundation

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Zinc deficiency has been found to be widespread among children in developing countries.Clinical and field studies have consistently observed an association between zinc deficiency and higher rates of infectious diseases, including skin infections, diarrhea, respiratory infections, malaria, and delayed wound healing. Based upon the impact of zinc deficiency on diarrheal disease alone, it is estimated correction of this deficiency could save 450,000 under-five deaths annually. What is the physiological explanation for this? Zinc has been identified to play critical roles in metallo-enzymes, poly-ribosomes, the cell membrane, and cellular function, leading to the understanding that it also plays a central role in cellular growth and in the function of the immune system. With zinc deficiency epithelial barriers are compromised and multiple components of the immune system malfunction. The obvious conclusion is that zinc deficiency results in diminished immunological competence that in turn leads to an increased risk for infectious diseases and greater severity of illnesses. Whether this is the case requires substantiation. A related, but more pragmatic question is the value added of zinc supplementation in addition to zinc treatment. The scale-up strategy being pursued in Bangladesh is to provide zinc for 10 days as a treatment at the time of a diarrhea episode. This is in accordance with recently revised WHO recommendations for the treatment of childhood diarrhea (WHO, in press). Can we conclude there is no or minimal value added to continuing zinc as a dietary supplement in zinc deficient children following an acute episode? If there is added benefit, can this be explained by improvement in zinc levels and/or immune function? The aims of this study include:1. In children six to twenty-four months of age with an acute episode of diarrhea attributable to enterotoxigenic E. coli (ETEC), to describe the innate and adaptive immune response to zinc and to relate changes in immune function or zinc status to the occurrence of repeat infectious illnesses over a 9 month period of observation. 2a. In children six to twenty-four months of age with an acute episode of diarrhea with enterotoxigenic E. coli (ETEC), and other non-ETEC diarrhea, to determine the value added of zinc supplementation following treatment in terms of the future occurrence of ACD, ARI, and impetigo and 2b. to assess the impact of zinc supplementation on health services utilization and household expenditures for ACD, ARI and impetigo.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diarrhoea
Keywords
Zinc treatment, supplementation, Enterotoxigenic E. coli, diarrhoea

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
338 (Anticipated)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Zinc
Primary Outcome Measure Information:
Title
To evaluate innate and adaptive immune response.
Title
Future occurrence of acute diarrhoea, ARI and impetigo.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
24 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children 6-24 months of age with acute childhood diarrheal illness. Exclusion Criteria: Severe dehydration, suspected cholera or pneumonia, chronic illness, bipedal edema (seriously ill children will be referred to ICDDR,B/Shishu Hospital). The child is currently receiving zinc (as a treatment or supplement) Wt/length, z-score below -3 (these children will be referred to ICDDR,B/ Shishu Hospital) Already participating in another study involving nutritional or therapeutic interventions
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Amit Saha, MBBS
Organizational Affiliation
International Centre for Diarrhoeal Disease Research, Bangladesh
Official's Role
Study Director
Facility Information:
Facility Name
ICDDR,B. Mirpur Field Site
City
Dhaka
ZIP/Postal Code
1212
Country
Bangladesh

12. IPD Sharing Statement

Citations:
PubMed Identifier
20237063
Citation
Sheikh A, Shamsuzzaman S, Ahmad SM, Nasrin D, Nahar S, Alam MM, Al Tarique A, Begum YA, Qadri SS, Chowdhury MI, Saha A, Larson CP, Qadri F. Zinc influences innate immune responses in children with enterotoxigenic Escherichia coli-induced diarrhea. J Nutr. 2010 May;140(5):1049-56. doi: 10.3945/jn.109.111492. Epub 2010 Mar 17.
Results Reference
derived

Learn more about this trial

Immunological and Clinical Responses to Zinc in Children With Diarrhoea

We'll reach out to this number within 24 hrs